Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995249 · ClinicalTrials.gov registry record · Phase 1
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
NCT05995249: Completed Phase 1 study, sponsored by Takeda.
NCT05995249 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 172 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (187% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05995249, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
The main aim of this study is to find out how the body of a healthy adult processes TAK-279 (pharmacokinetics) when substances that either hinder or help the human metabolism such as erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn about side effects and how well it is tolerated when TAK-279 is given alone and together with substances that impact human metabolism. The participants will need to stay at the clinic for up to 26 days.
Interventions
- DRUG TAK-279
- DRUG Erythromycin
- DRUG Efavirenz
- DRUG Phenytoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
What the finished NCT05995249 record still lists
NCT05995249 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (187% higher).
The record links to 0 conditions, and to 4 interventions - of which TAK-279 is the first listed.
NCT05995249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05995249 about?
NCT05995249 is a clinical study titled "A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults". The main aim of this study is to find out how the body of a healthy adult processes TAK-279 (pharmacokinetics) when substances that either hinder or help the human metabolism such as erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn about side effects and how ...
What is the current status of trial NCT05995249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2023-08-11. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05995249?
The interventions under investigation include: TAK-279 (DRUG), Erythromycin (DRUG), Efavirenz (DRUG), Phenytoin (DRUG).
Who is sponsoring clinical trial NCT05995249?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05995249's enrollment target sits among peer trials
172 324th of 2000 higher than 1,677 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI